Piper Sandler Initiates Coverage On Relmada Therapeutics with Overweight Rating, Announces Price Target of $12

Benzinga Newsdesk www.benzinga.com Neutral 57.9%

Neg 0% Neu 57.9% Pos 0%

Piper Sandler analyst Kelsey Goodwin initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Overweight rating and announces Price Target of $12.